Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Solutions Reports Disappointing Revenue, Widened Loss in Q4

NEW YORK, Feb. 14 - Genomic Solutions on Thursday posted slumping revenue atop a wider loss following its acquisition of Cartesian Technologies.

 

Revenue for the period ended Dec. 31 was $4.4 million compared with $5.5 million one year ago, results that the company said had missed expectations.

 

R&D spending in the quarter also fell, to $1.4 million from $1.5 million last year while restructuring costs, pegged at $8.6 million, made up the brunt of Genomic Solutions' expenses for the quarter.

 

As a result, net loss was $12.3 million, or $.49 per share, for the fourth quarter 2001 compared with $1.3 million, or $.05, year over year. Genomic Solutions had $13.1 million in the bank at the end of the quarter.

 

"While 2001 did not meet our financial expectations, we made significant strides toward profitability and implementation of our business plan with our cost reduction initiatives and our acquisition of Cartesian Technologies," which closed on Dec. 18, said Jeffrey Williams, president and CEO of Genomic Solutions.

 

Looking ahead, the company said that revenue "will exceed $30 million." Total revenue in fiscal 2001 was $17 million, which well from $19 million in 2000.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.